Theravance Biopharma confirmed a Phase 3 failure for ampreloxetine in multiple system atrophy and announced an immediate wind‑down of its R&D organization and a 50% workforce reduction. The company said the trial missed its primary endpoint, prompting abandonment of ampreloxetine and a strategic pivot to focus on its marketed respiratory product, Yupelri, and cash preservation measures estimated to cut burn by roughly 60%. Executives framed the move as fiscal triage to preserve core commercial operations while the board explores strategic options, including a sale. The decision underscores the binary financial risks small‑ and mid‑cap biotechs face when late‑stage readouts fail and highlights investor scrutiny on clinical proof‑points that determine company viability.